Related Experiment Video
Updated: Jun 5, 2026
Isolation of Adipose Derived Regenerative Cells for the Treatment of Erectile Dysfunction Following Radical Prostatectomy
Published on: December 28, 2021
Evaluation of degarelix in the management of prostate cancer
1Department of Urology, University Hospitals Leuven, Campus Gasthuisberg, Leuven, Belgium.
Abstract:
Medical castration using gonadotropin-releasing hormone (GnRH) receptor agonists currently provides the mainstay of androgen deprivation therapy for prostate cancer. Although effective, these agents only reduce testosterone levels after a delay of 14 to 21 days; they also cause an initial surge in testosterone that can stimulate the cancer and lead to exacerbation of symptoms ("clinical flare") in patients with advanced disease. Phase III trial data for the recently approved GnRH receptor blocker, degarelix, demonstrated that it is as effective and well tolerated as GnRH agonists. However, it has a pharmacological profile more closely matching orchiectomy, with an immediate onset of action and faster testosterone and PSA suppression, without a testosterone surge or microsurges following repeated injections. As a consequence, with this GnRH blocker, there is no risk of clinical flare and no need for concomitant antiandrogen flare protection. Degarelix therefore provides a useful addition to the hormonal armamentarium for prostate cancer and offers a valuable new treatment option for patients with hormone-sensitive advanced disease. Here, we review key preclinical and clinical data for degarelix, and look at patient-focused perspectives in the management of prostate cancer.
Insights
Degarelix, a gonadotropin-releasing hormone (GnRH) receptor blocker, offers immediate testosterone suppression for advanced prostate cancer without the initial surge seen with GnRH agonists.
Area of Science:
- Oncology
- Endocrinology
- Pharmacology
Background:
- Androgen deprivation therapy (ADT) is standard for advanced prostate cancer.
- Gonadotropin-releasing hormone (GnRH) receptor agonists are widely used for ADT.
- GnRH agonists have a delayed onset of action and can cause a testosterone surge, leading to clinical flare.
Purpose of the Study:
- To review preclinical and clinical data for degarelix.
- To evaluate degarelix as an alternative to GnRH agonists in prostate cancer treatment.
- To discuss patient-focused perspectives on degarelix therapy.
Main Methods:
- Review of key preclinical studies on degarelix.
- Analysis of Phase III clinical trial data comparing degarelix to GnRH agonists.
- Examination of degarelix's pharmacological profile, including onset of action and testosterone suppression kinetics.
Main Results:
- Degarelix demonstrates efficacy and tolerability comparable to GnRH agonists.
- Degarelix provides immediate testosterone suppression, mimicking orchiectomy.
- Degarelix avoids the testosterone surge and clinical flare associated with GnRH agonists, eliminating the need for antiandrogen co-administration.
Conclusions:
- Degarelix is a valuable new treatment option for hormone-sensitive advanced prostate cancer.
- Its rapid onset and lack of flare make it a favorable alternative to GnRH agonists.
- Degarelix enhances the hormonal armamentarium for prostate cancer management.
